Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
PLoS One. 2020 Dec 1;15(12):e0239670. doi: 10.1371/journal.pone.0239670. eCollection 2020.
Reactive oxygen species modulator 1 (romo1) causes cell hyperplasia and promotes cancer cell invasion. Based recent studies, the overexpression of romo1 is associated with lymphatic metastasis and poor prognosis in lung cancer. We aimed to evaluate associations between romo1 expression and lymph node metastasis in non-small cell lung cancer (NSCLC). Clinical data and pathological results were retrospectively reviewed for 98 subjects diagnosed with NSCLC and who underwent surgical biopsy between 1994 and 2009. A total 98 tumor specimens were analyzed. The romo1 H score was correlated with stage and was significantly higher in subjects with lymph node metastasis than in those without metastasis (173 vs 116; P < 0.05). The area (%) of grade 1 expression was significantly smaller (19.5 vs 37.0; P = 0.005) and the area of grade 3 expression was significantly larger (27.9 vs 6.00; P < 0.001) in subjects with lymph node metastasis than in those without metastasis. In stage I patients, disease free survival (DFS) (191 ± 18.8 vs. 75.6 ± 22.4 months, P = 0.004) was significantly longer in the low romo1 group than in the high romo1 group. A multivariate analysis showed a significant association between high romo1 expression and poor DFS (hazard ratio 5.59, 95 confidence interval, 1.54-20.3, P = 0.009). These findings support the prognostic value of romo1 in NSCLC, especially in stage I.
活性氧物种调节剂 1（romo1）可引起细胞增生，并促进癌细胞侵袭。基于最近的研究，romo1 的过表达与肺癌的淋巴转移和预后不良有关。我们旨在评估 romo1 表达与非小细胞肺癌（NSCLC）淋巴结转移之间的关系。回顾性分析了 1994 年至 2009 年间接受手术活检的 98 例 NSCLC 患者的临床资料和病理结果。共分析了 98 例肿瘤标本。romo1 H 评分与分期相关，在有淋巴结转移的患者中明显高于无转移的患者（173 比 116；P < 0.05）。有淋巴结转移的患者中 1 级表达的面积（%）明显较小（19.5 比 37.0；P = 0.005），而 3 级表达的面积明显较大（27.9 比 6.00；P < 0.001）。在 I 期患者中，低 romo1 组的无病生存期（DFS）（191 ± 18.8 比 75.6 ± 22.4 个月，P = 0.004）明显长于高 romo1 组。多因素分析显示，高 romo1 表达与较差的 DFS 显著相关（风险比 5.59，95%置信区间，1.54-20.3，P = 0.009）。这些发现支持 romo1 在 NSCLC 中的预后价值，尤其是在 I 期。
